Tokyo, October 20, 2016 -- Moody's Japan K.K. says that the expiry of key drug patents over the next 1-3 years will pressure the revenues of the rated Japanese pharmaceutical companies, and could prompt the formation of strategic allegiances and acquisitions.

Vollständigen Artikel bei Moodys lesen